Steps to better understand severe asthma in adults
|
|
- Shona O’Connor’
- 5 years ago
- Views:
Transcription
1 PRESCRIBING IN PRACTICE n Steps to better understand severe asthma in adults Alexandra M Nanzer MRCP and Andrew Menzies-Gow PhD, MB BS Primary care plays an essential role in identifying and supporting a patient with undertreated or difficult to treat asthma. Over five million people in the UK are currently receiving treatment for asthma and the NHS spends around 1 billion a year caring for them. In the majority of cases, patients can live normal lives with minimal impact on their daily activities. Yet, an estimate of 140 patients per million population suffer from severe asthma and remain symptomatic despite correct treatment. In the UK, three people die every day from asthma. 3 There is a substantial unmet clinical need to improve treatment outcomes and to reduce the large socioeconomic burden associated with severe asthma. 5 Over the last decade significant effort has been put into place to address the management of severe asthma and a number of severe asthma networks have been established in the UK to help implement this. The first step to better understand severe asthma is a systematic evaluation and definition of the disease. Asthma UK estimates that 75 per cent of hospital admissions for asthma are avoidable and that two in three deaths from asthma are preventable. A recent comprehensive review into asthma deaths revealed that 45 per cent of patients had not called for help during a fatal asthma attack. 3 This suggests that patients might not have been aware of the severity of their disease and/or did not recognise warning symptoms. Primary care plays an essential role in identifying and supporting a patient with undertreated or difficult to treat asthma. Severe asthma is associated with fungal and/or mould sensitivity with up to a quarter of patients with persistent symptoms testing positive on skin tests for Aspergillus or other fungi Assessment Assessment of a patient presenting with recurrent episodes of wheeze, chest tightness and/or cough requires a careful history focusing on symptoms, exacerbating triggers, occupational and environmental factors and mental health. Patients with difficult-to-control asthma characteristically suffer from untreated or undertreated co-morbidities. There is a high prevalence of co-existing psycho - social factors that may contribute to dysfunctional breathing or vocal cord dysfunction and continuous allergen exposure may also contribute to the persistence of symptoms in patients with difficult asthma. Non-adherence to asthma medication has frequently been identified as the most common factor leading to poorly controlled asthma with studies demonstrating that patients take only up to 50 per cent of their prescribed medication correctly. 8 Poor technique can reduce SPL Prescriber 19 May 2015 z 29
2 n PRESCRIBING IN PRACTICE l Severe asthma GORD Obstructive sleep apnea Obesity Mental health problems Smoking Allergies and/or chronic rhinosinusitis Fungal sensitivity Table 1. Co-morbidities that may mimic asthma symptoms and/or contribute to asthma severity drug efficacy to as low as 10 per cent and no patient should be given a device without prior education on how to use it. 9 When assessing a patient with continuous asthma symptoms it is important to investigate for co-morbidities. Atopic rhinosinusitis, fungal sensitivity, gastrooesophageal reflux disease (GORD), obesity and obstructive sleep apnoea (OSA) all have the potential to exacerbate asthma (see Table 1). Asthma may be further complicated by bronchiectasis, recurrent aspiration, intratracheal tumours, heart failure or tracheomalacia. Atopy Allergies are less common in severe asthma as compared to mild asthma, but there is a high prevalence of chronic rhinosinusitis and nasal polyposis. 10 Severe asthma is seen more frequently in aspirin exacerbated respiratory disease (AERD), where the majority of patients suffer from nasal polyposis. 11 Fungal sensitivity Severe asthma, and in particular asthma prone to frequent exacerbations, is associated with fungal and/or mould sensitivity with up to a quarter of patients with persistent symptoms testing positive on skin tests for Aspergillus or other fungi. 12 Fungi can cause damage to the host either by acting as an aeroallergen or by causing infection. Patients with persistently uncontrolled asthma are often chronically colonised with Aspergillus, Candida, Penicillium, and Curvularia species Positive skin test, an elevated total IgE and specific IgE and IgG are all diagnostic criteria for allergic bronchopulmonary aspergillosis (ABPA). ABPA can be found in 10 to 25 per cent of patients with severe asthma and has therapeutic implications in that some patients might benefit from antifungal treatment. Patients with evidence of fungal sensitisation who do not meet the criteria for ABPA are characterised as suffering from severe asthma with fungal sensitisation (SAFS). 15 GORD Patients with GORD typically suffer from cough and chest tightness, symptoms that can aggravate or mimic asthma. GORD has been reported to be prevalent in between 12 to 85 per cent of patients with asthma. Adequate treatment of reflux symptoms results in improved asthmarelated quality of life by reducing nocturnal symptoms and exacerbation frequency and some studies report reduction in the use of short-acting beta 2 agonists. 16 Obesity We are observing an epidemic increase in obesity, which is an independent risk factor for asthma. Treatment of obesityrelated asthma with inhaled or oral corticosteroids often proves disappointing. Yet, there is clear evidence that weight loss improves asthma control with studies demonstrating a reversal of the proinflammatory cytokine milieu seen in severe asthma after bariatric surgery. 17,18 Obstructive sleep apnoea Snoring, observed apnoea and poorlycontrolled asthma are closely linked and patients with OSA and nocturnal asthma may have similar clinical presentations. 19 Treatment with continuous positive airway pressure (CPAP) has the potential to improve asthma-related quality of life, lung function and to reduce short-acting beta 2 agonist requirements. 20 Psychiatric disorders Many patients with chronic diseases suffer from anxiety and depression. They have more frequent disease exacerbations and increased healthcare utilisation, and severe asthmatics are no exception to this, especially prednisolonedependent patients. 21 Smoking Smoking with asthma results in a more rapid decline in lung function, and more Consistently poor symptom control: Asthma Control Questionnaire score (ACQ) consistently >1.5 or Asthma Control Test (ACT) <20 Frequent severe exacerbations requiring at least two courses of oral corticosteroids for a minimum of three days in the previous year One or more hospitalisation, intensive care unit admission or invasive ventilation in the previous year FEV 1 <80% predicted (with FEV 1 /FVC reduced to less than the lower limit of normal) Table 2. A patient suffering from any of the criteria listed needs to be considered for referral to a specialised asthma centre unscheduled healthcare visits and exacerbations, and smokers have higher anxiety and depression scale scores than non-smokers. 22 Smokers also have an impaired response to corticosteroids and as such are more likely to have poor symptom control. 23 It is therefore imperative that patients who smoke should be offered help in quitting. Asthma exacerbations Asthma exacerbations are defined as an increase in a patient s symptoms requiring intensified treatments and/or unscheduled healthcare utilisation. Recurrent exacerbations are associated with a progressive decline in lung function and a high risk of severe morbidity and death; it is, therefore, critically important to identify patients at risk of exacerbating. Previous exacerbations, a predicted FEV 1 <76 per cent, high levels for exhaled nitric oxide (>28ppb) and high sputum eosinophil counts have all been associated with a higher risk of asthma exacerbations and are helpful clinical biomarkers. 24 The recognition of co-morbidities and exacerbation risks in every patient with severe asthma is fundamental to goodquality asthma management in primary care. Time and resource limitations in primary care necessitate referral of those with the most challenging and obstinate symptoms and is of key importance for a patient with severe asthma. The National Review on Asthma Deaths (NRAD) found 30 z Prescriber 19 May 2015
3 Severe asthma l PRESCRIBING IN PRACTICE n that 43 per cent of patients who died had not had a review in primary care during the past year, and often warning signs had not been acted on. 3 Referral Patients should be considered to suffer from severe asthma after an alternative diagnosis has been excluded, co-morbidities have been treated, allergen avoidance strategies are in place and adherence with treatment and inhaler technique has been checked. Also, the severity of asthma can change over time, stressing the need for vigilant monitoring in primary care. The 2013 international ERS/ATS guidelines classify severe asthma as a disease that requires treatment with high doses of inhaled corticosteroids (ICS) and/or systemic corticosteroids in order to obtain symptom control or which remains problematic despite this therapy. 25 Any of the criteria outlined in Table 2 qualifies a patient as having on - going symptoms and therefore severe asthma that needs referring to a specialist centre that offers a multidisciplinary service utilising a team experienced in the assessment and management of difficult asthma. 26 Severe asthma requires systematic evaluation for confounding factors and exacerbating triggers and, equally importantly, confirmation that asthma is the correct diagnosis by a multidisciplinary team. Systematic assessment has the potential to identify up to half of previously deemed severe asthmatics as difficult-to-treat asthmatics. 27 Treatment Most patients with severe asthma require treatment according to Step 4 or 5 of the BTS/SIGN asthma guideline, 26 ie a longacting beta agonist (LABA) and high-dose ICS. Another option at Step 4 is to combine two long-acting broncho dilators with different modes of action. In two replicate randomised controlled trials in 912 patients the addition of tiotropium to ICS and LABA has been shown to sustain bronchodilation over 24 hours and to significantly reduce exacerbation rates when compared to placebo over a period of 48 weeks. 28 Further treatment options on Step 4 of the treatment ladder include leukotriene antagonists and/or slowrelease theophylline and, according to Step 5, continuous or frequent courses of oral corticosteroids. Methotrexate is a valid agent in patients who, despite long-term treatment with oral corticosteroids, fail to gain satisfactory control of their asthma. 29 Due to its substantial side-effect profile it is advised that only physicians with expertise in severe asthma prescribe methotrexate. Continuous prophylactic treatment with a macrolide antibiotic has been proven effective in respiratory diseases due to their anti-inflammatory and immune-modulatory activity. Studies have shown a reduction in severe exacerbations in patients with non-eosinophilic asthma and a significant improvement in the Asthma Quality of Life Questionnaire score. 30 However, a growing risk of population resistance to antibiotics means treatment should be carefully considered and restricted to severe asthma patients with frequent infective exacerbations. Despite these treatment options, a number of patients remain symptomatic on a daily basis with their lives not only affected by a chronic disease, but are further impacted by the numerous and serious side-effects of oral corticosteroids. For most patients with severe asthma, standard treatment is not sufficiently effective. Severe asthma is particularly heterogeneous in its nature and certain types of patients will respond better to specific therapies than others. For the future, phenotype-specific therapies promise enhanced treatment success. 31 Much effort has been directed at characterising severe asthma subgroups or phenotypes. The Severe Asthma Research Program (SARP) identified distinct subphenotypes by unbiased cluster analysis (see Table 3). 32 Recent advances A number of exciting therapies have been developed to improve severe asthma management. Biologicals directed against specific cytokines that are key players in driving the inflammatory process in asthma promise new therapeutic possibilities and more individualised asthma management. Omalizumab Omalizumab (Xolair) remains so far the most successfully applied monoclonal antibody to treat allergic asthma by reducing the exacerbation rate. Current NICE guidelines recommend omalizumab as an option for treating severe, persistent and confirmed allergic IgE-mediated asthma as an add on to optimised standard therapy in patients who need continuous or frequent (defined as four or more courses in the previous year) treatment with oral corticosteroids. A number of studies have demonstrated significant improvements in asthma-related symptoms allowing the patient to reduce the dose of corticosteroids and frequency of rescue inhaler It appears that patients with blood eosinophilia and high levels of exhaled Early-onset allergic asthma Characterised by atopy and a generally good clinical response to corticosteroids and, if indicated, anti-ige treatment. Immunologically driven by Th-2 cells. Late-onset eosinophilic asthma Distinguished by high sputum eosinophilia, has a poor response to corticosteroids. More frequently seen in males. Novel promising treatments include anti-il-5. Obesity-related asthma Associated with adult onset and corticosteroid insensitivity and more frequently seen in women. Non-eosinophilic. Neutrophilic asthma Sputum neutrophils and poor response to corticosteroids. Table 3. Severe asthma sub-phenotypes 34 Prescriber 19 May 2015 z 31
4 n PRESCRIBING IN PRACTICE l Severe asthma nitric oxide most benefit from anti-ige treatment. 36 There is further evidence emerging that omalizumab may have a role in non-atopic asthma. A recent trial demonstrated significantly increased asthma control and a trend to reduced exacerbation rates and improved lung function in nonatopic asthma. 37,38 Patients need to be made aware that treatment has to be given regularly, on a long-term basis and in specialist centres only. Novel therapies Promising novel treatments with steroid sparing potential targeting the cytokine pathway include the anti-interleukin-5 (anti-il-5) antibody mepolizumab. Mepolizumab treatment has been shown to significantly reduce exacerbations and oral corticosteroid doses in patients with eosinophilia in blood and sputum. 39 In the DREAM (Dose Ranging Efficacy and Safety with Mepolizumab in Severe Asthma) study mepolizumab was well tolerated and displayed a good safety profile and efficacy in 621 patients over a one-year period. 39 Clinical trials have also investigated targeted therapies against the Th2 cytokines IL-4 and IL-13. Periostin is a serum protein induced by IL-13, a key cytokine orchestrating bronchial hyperresponsiveness, inflammation and airway fibroblast proliferation. It has proven to be an important prognostic biomarker for treatment with the anti-il- 13 antibody lebrikizumab. A recent study demonstrated that treatment with lebrikizumab increased FEV 1 in patients with a high serum periostin level. 40 Other therapies under development, and yet to show any clear clinical benefit, are listed in Table 4. Vitamin D There has been a considerable amount of literature published linking deficiency in serum vitamin D status to chronic inflammatory lung disease such as asthma. 41 Reports have shown a positive correlation between vitamin D deficiency and asthma prevalence, asthma exacerbation rate and hospital admissions Studies suggest a role for vitamin D in severe asthma that is less responsive to corticosteroid treatment. 45,46 Anti-IL-17 antibodies 1 Anti-IL-9 antibodies 2 Agents targeting thymic stromal lymphopoietin (TSLP) 4 Chemokine inhibitors (CCR3, CCR4) 6 Phosphodiesterase and kinase inhibitors 7 Table 4. Other asthma therapies currently under development but have yet to show any clear clinical benefit Non-pharmacological therapy Chronic airway inflammation and structural changes in the airways, termed airway remodelling, are a distinct feature in severe asthma. Smooth muscle hyper - plasia is a significant component of airway remodeling. Applying radiofrequency energy to sub segmental airways has been shown to reduce muscle mass at the site of thermoplasty. Trials investigating the effect of bronchial thermoplasty demonstrated a reduction in the number of severe asthma exacerbations and improvement in asthma-specific quality of life 47 and a recent study found no adverse events after a five-year follow up period. 48 Although guidelines recommend bronchial thermoplasty for adults with severe asthma that is not controlled on inhaled corticosteroids and LABAs, it is currently unclear which phenotypes respond best to this treatment. Studies are needed to identify the phenotype of patients that will derive significant clinical benefit most from this invasive procedure. Conclusion Asthma is a common disease and in most cases responds well to standard treatment. Severe asthma affects a minority of patients, yet they remain an ongoing challenge for healthcare professionals. A multidisciplinary systematic approach to diagnosis and treatment is essential and allows for the assessment of novel treatments for carefully-selected patients. GPs should consider referring patients who fulfil any of the severe asthma criteria to specialised centres for further investigations and management. Within the next 5 10 years multiple targeted therapies should become available that have the potential to revolutionise severe asthma care and end our dependence on oral corticosteroids for this patient population. Recommended reading New treatments for severe treatment-resistant asthma: targeting the right patient. Chung KF. Lancet Respir Med 2013;1: Tiotropium for asthma promise and caution. Bel EH. N Engl J Med 2012;367: Tiotropium in asthma poorly controlled with standard combination therapy. Kerstjens HA. N Engl J Med 2012;367: Safety of bronchial thermoplasty in patients with severe refractory asthma. Pavord ID. Ann Allergy Asthma Immunol 2013;111: Characterisation of an OCS-dependent severe asthma population treated with mepolizumab. Prazma CM. Thorax 16 May Lebrikizumab treatment in adults with asthma. Corren J. N Engl J Med 2011;365: British guidelines on the management of asthma: what s new for 2011? Turner S. British Guidelines on the Management of Asthma. Thorax 2011;66: References 1. Busse WW, et al. Am J Respir Crit Care Med 2013;188: Parker JM, et al. BMC Pulm Med;11: Torjesen I. BMJ 2014;348:g Edwards MJ. Drug News Perspect 2008; 21: Braman SS. Chest 2006;130:4S 12S. 6. Catley MC, et al. Pharmacol Ther 2011;132: Barnes PJ. Trends Pharmacol Sci 2010; 31: Gamble J, et al. Am J Respir Crit Care Med 2009;180: Sumino K, Cabana MD. Curr Opin Pulm Med 2013;19: Chung SD, et al. Laryngoscope 2014;124: Choi JH, et al. Curr Opin Allergy Clin Immunol 2014;14: Denning DW, et al. Eur Respir J 2006;27: Salo PM, et al. J Allergy Clin Immunol 2006;118: Bush RK, Prochnau JJ. J Allergy Clin Immunol 2004;113: Denning DW, et al. Clin Transl Allergy 2014;4: Kiljander TO, et al. Chest 1999;116: Gibson PG. Ann Am Thorac Soc 2013;10: S Toh JJ, et al. Obes Surg 2014;24: Yigla M, et al. J Asthma 2003;40: z Prescriber 19 May 2015
5 Severe asthma l PRESCRIBING IN PRACTICE n 20. Alkhalil M, et al. Ann Allergy Asthma Immunol 2008;101: Amelink M, et al. Respir Med 2014;108: Thomson NC, et al. J Allergy Clin Immunol 2013;131: Pietinalho A, et al. Allergy 2009;64: Gelb AF, et al. Chest 2006;129: Chung KF, et al. Eur Respir J 2014;43: BTS/SIGN. British Guideline on the Management of Asthma. A national clinical guideline. May 2008 (Revised January 2012). 27. Gibeon D, et al. Chest 2015 doi: / chest Kerstjens HA, et al. N Engl J Med 2012; 367: Davies H, et al. Cochrane Database Syst Rev 2000;(2):CD Brusselle GG, et al. Thorax 2013;68: Wenzel SE. Nat Med 2012;18: Moore WC, et al. Am J Respir Crit Care Med 2010;181: Busse WW. Am J Respir Crit Care Med 2001;164:S Grimaldi-Bensouda L, et al. Chest 2013; 143: Holgate S, et al. J Allergy Clin Immunol 2005;115: Hanania NA, et al. Am J Respir Crit Care Med 2013;187: De Llano LP, et al. J Asthma 2013;50: Garcia G, et al. Chest 2013;144: Pavord ID, et al. Lancet 2012;380: Corren J, et al. N Engl J Med 2011;365: Autier P, et al. Lancet Diabetes Endocrinol 2014;2: Bener A, et al. Int Arch Allergy Immunol 2012;157: Paul G, et al. Am J Respir Crit Care Med 2012;185: Brehm JM, et al. Am J Respir Crit Care Med 2009;179: Gupta A, et al. Am J Respir Crit Care Med 2011;184: Nanzer AM, et al. J Allergy Clin Immunol 2013;132: e Castro M, et al. Am J Respir Crit Care Med 2010;181: Wechsler ME, et al. J Allergy Clin Immunol 2013;132: Declaration of interests Dr Nanzer has none to declare. Dr Menzies-Gow has attended advisory boards for Roche, Mundi Pharma, Boeringher Ingelheim, Amgen and Johnson and Johnson. He has also received lecture fees from Novartis, NAPP and GlaxoSmithKline, and attended international conferences with Novartis and Boeringher Ingelheim. Dr Nanzer is a specialist registrar in respiratory medicine and Dr Menzies-Gow is a consultant in respiratory medicine, Royal Brompton & Harfield NHS Foundation Trust, London Prescriber 19 May 2015 z 33
Prof Neil Barnes. Respiratory and General Medicine London Chest Hospital and The Royal London Hospital
Prof Neil Barnes Respiratory and General Medicine London Chest Hospital and The Royal London Hospital ASTHMA: WHEN EVERYTHING FAILS WHAT DO YOU DO? South GP CME 2013, Dunedin Saturday 17 th August 2013
More informationDo We Need Biologics in Pediatric Asthma Management?
Do We Need Biologics in Pediatric Asthma Management? Ting Fan LEUNG, MBChB, MD, FRCPCH, FAAAAI Professor and Chairman Department of Paediatrics The Chinese University of Hong Kong Asthma and Allergy by
More informationBiologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital
Biologics in asthma Are we turning the corner? Roland Buhl Pulmonary Department Mainz University Hospital Biologics in asthma - are we turning the corner? Allergic asthma anti - IgE Allergic airway inflammation
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationBiologic Therapy in the Management of Asthma. Nabeel Farooqui, MD
Biologic Therapy in the Management of Asthma Nabeel Farooqui, MD None Disclosures Objectives Define severe asthma phenotypes and endotypes Describe the role of biologics in asthma management Review pivotal
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationWhat s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals
What s new in Asthma? Dr Alexandra Nanzer-Kelly Consultant Respiratory Physician Royal Brompton and Harefield Hospitals Asthma is an inflammatory disease Relaxed smooth muscles Air trapped in alveoli Tightened
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationBiologics in Asthma: Present and Future
Biologics in Asthma: Present and Future Flavia Hoyte, MD Associate Professor of Medicine Fellowship Training Program Director Division of Allergy and Immunology National Jewish Health and University of
More informationPhenotypes of asthma; implications for treatment. Medical Grand Rounds Feb 2018 Jim Martin MD DSc
Phenotypes of asthma; implications for treatment Medical Grand Rounds Feb 2018 Jim Martin MD DSc No conflicts to declare Objectives To understand the varied clinical forms of asthma To understand the pathobiologic
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationSEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI IL-5 ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA
SEVERE ASTHMA NUCALA 100MG SUBCUTANEOUS INJECTION THE FIRST TARGETED ANTI ADD-ON TREATMENT FOR ADULTS WITH SEVERE REFRACTORY EOSINOPHILIC ASTHMA FIND OUT MORE VISIT - WWW.NUCALA.CO.UK Vial not actual size
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More informationAdd on therapy in asthma. Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes
Add on therapy in asthma Local experience in context J Paul Dilworth, Nicola Marks, Lauren Geddes Programme Omalizumab Evidence and assessment Local Experience Dysfunctional breathing The other effective
More informationAsthma Therapy 2017 JOSHUA S. JACOBS, M.D.
Asthma Therapy 2017 JOSHUA S. JACOBS, M.D. BACKGROUND-PREVALENCE Asthma is one of the most common chronic diseases worldwide with an estimated 300 million affected individuals Prevalence is increasing
More informationClinical Implications of Asthma Phenotypes. Michael Schatz, MD, MS Department of Allergy
Clinical Implications of Asthma Phenotypes Michael Schatz, MD, MS Department of Allergy Definition of Phenotype The observable properties of an organism that are produced by the interaction of the genotype
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationUpdate on Biologicals for ABPA and Asthma
Update on Biologicals for ABPA and Asthma 5 th Advances Against Aspergillosis Istanbul 27 Jan 2012 Richard B. Moss MD Professor of Pediatrics Stanford University Palo Alto CA USA Disease of chronic airway
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationManaging severe asthma in adults: lessons from the ERS/ATS guidelines
REVIEW C URRENT OPINION Managing severe asthma in adults: lessons from the ERS/ATS guidelines Kian Fan Chung a,b Purpose of review To review the latest guidelines on severe asthma. Recent findings An updated
More informationCurrent Asthma Therapy: Little Need to Phenotype. Phenotypes of Severe Asthma. Cellular Phenotypes 12/7/2012
Subbasement Membrane Thickness(µm) 12/7/212 Current Asthma Therapy: Little Need to Phenotype Phenotypes of Severe Asthma Most mild and to some degree moderate asthmatics respond well to currently available
More informationDifferent kinds of asthma, different kinds of therapies
Different kinds of asthma, different kinds of therapies Friday 10 th November 2017 XXXIII Congresso Sezione SIAAIC Toscana Professor Neil Barnes Medical Head Global Respiratory Franchise, GSK Brentford,
More informationTraiter l asthme sévère par le phénotype. Dr. Alain Michils CUB-Hôpital Erasme
Traiter l asthme sévère par le phénotype Dr. Alain Michils CUB-Hôpital Erasme Darwin 25 mars 2017 Step 5 treatment (GINA 2016) STEP 5 STEP 4 PREFERRED CONTROLLER CHOICE STEP 1 STEP 2 Low dose ICS STEP
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationDisclosures. Learning Objective. Biological therapies. Biologics with action against 11/30/2011. Biologic Asthma Therapies and Individualized Medicine
Biologic Asthma Therapies and Individualized Medicine Mark S. Dykewicz, MD Director, Allergy & Immunology Fellowship Program Director Wake Forest University School of Medicine Winston-Salem, North Carolina
More informationAsthma - Chronic. Presentations of asthma Cough Wheeze Breathlessness Chest tightness
Asthma - Chronic Definition of asthma Chronic inflammatory disease of the airways 3 components: o Reversible and variable airflow obstruction o Airway hyper-responsiveness to stimuli o Inflammation of
More informationSevere Asthma & Exacerbations: Dawn of a New Era?
Severe Asthma & Exacerbations: Dawn of a New Era? Christophe von Garnier Department of Pulmonary Medicine Syndromes, Phenotypes & Endotypes Asthma Syndrome Variable symptoms, expiratory airflow limitation,
More informationRecent changes in the drug treatment of allergic asthma
DRUG THERAPIES IN Clinical Medicine 2013, Vol 13, No 5: 477 81 Recent changes in the drug treatment of allergic asthma David Gibeon and Andrew Menzies-Gow ABSTRACT Asthma is a heterogeneous condition with
More informationDedicated Severe Asthma Services Improve Health-care Use and Quality of Life
[ Original Research Asthma ] Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life David Gibeon, MBChB ; Liam G. Heaney, MD ; Chris E. Brightling, PhD, FCCP ; Rob Niven, MD ; Adel
More informationUpdate on management of respiratory symptoms. Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT
Update on management of respiratory symptoms Dr Farid Bazari Consultant Respiratory Physician Kingston Hospital NHS FT Topics The common respiratory symptoms Cough: causes, diagnosis and therapy Update
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationTHE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
More informationAmanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ
Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute Scottsdale, AZ Financial Disclosures Advanced Practiced Advisory Board for Circassia Learning Objectives 1. Briefly
More informationAsthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches
Asthma and Its Many Unmet Needs: Directions for Novel Therapeutic Approaches William W. Busse,, M.D. University of Wisconsin School of Medicine and Public Health Madison, WI, USA Disclosure Slide Employment
More informationAsthma: diagnosis and monitoring
Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationAsthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient
Asthma Hetereogeneity, Phenotypes and Endotypes Choosing the Right Biologic for your Patient Mario Castro MD, MPH Asthma & Airway Translational Research Unit Washington University School of Medicine St.
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Michigan Society for Respiratory Care Monday, October 5, 2015 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry
More informationSomkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University
Somkiat Wongtim Professor of Medicine Division of Respiratory Disease and Critical Care Chulalongkorn University Asthma-related Comorbidities Comorbid conditions of the upper airways Rhinitis and Sinusitis
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More informationPharmacy Management Drug Policy
SUBJECT: : Nucala (mepolizumab), Cinqair (reslizumab), & Fasenra (benralizumab) POLICY NUMBER: Pharmacy-62 EFFECTIVE DATE: 12/15 LAST REVIEW DATE: 3/5/2018 If the member s subscriber contract excludes
More informationManagement of Severe Asthma Including Biologics and Bronchial Thermoplasty. Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC
Management of Severe Asthma Including Biologics and Bronchial Thermoplasty Karen L. Gregory, DNP, APRN, CNS, RRT, AE-C, FAARC Disclosures ALK speaker Monaghan Medical Corporation speaker Novartis speaker
More informationDiagnosis and Management of Fungal Allergy Monday, 9-139
Diagnosis and Management of Fungal Allergy Monday, 9-139 13-2010 Alan P. Knutsen,, MD Director, Pediatric Allergy & Immunology Director, Jeffrey Modell Diagnostic Center for Primary Immunodeficiencies
More informationAsthma in Day to Day Practice
Asthma in Day to Day Practice VIJAY.K.VANAM Financial relationships: Disclosures Employed at Mercy Medical Center, Mason City. Nonfinancial relationships: I receive no financial gain from any pharmaceutical
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More information2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)
A3D3 2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL) SECTION B PART 1 - SERVICE SPECIFICATIONS Service Specification No.
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationIdentifying Biologic Targets to Attenuate or Eliminate Asthma Exacerbations
Identifying Biologic Targets to Attenuate or Eliminate Exacerbations exacerbations are a major cause of disease morbidity and costs. For both children and adults, viral respiratory infections are the major
More informationLearning the Asthma Guidelines by Case Studies
Learning the Asthma Guidelines by Case Studies Timothy Craig, DO Professor of Medicine and Pediatrics Distinguished Educator Penn State University Hershey Medical Center Objectives 1. Learn the Asthma
More informationAsma e BPCO: le strategie terapeutiche
Asma e BPCO: le strategie terapeutiche Dott. Marco Contoli ctm@unife.it Sezione di Medicina Interna e Cardio-Respiratoria Dipartimento di Scienze Mediche Università di Ferrara COPD Definition Chronic Obstructive
More informationAsthma Upate 2018: What s New Since the 2007 Asthma Guidelines of NAEPP?
10:50-11:50am Asthma Update 2018: What s New Since the 2007 National Asthma Guidelines? SPEAKER Christopher H. Fanta, MD Disclosures The following relationships exist related to this presentation: Christopher
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationBRONCHIAL THERMOPLASTY
Review Article 155 BRONCHIAL THERMOPLASTY Prince James* and Richa Gupta* (Received on 4.5.2010; Accepted after revision on 5.9.2011) Summary: Even with the use of maximum pharmacological treatment, asthma
More informationLINEE GUIDA DELL ASMA: UP TO DATE
LINEE GUIDA DELL ASMA: UP TO DATE Azienda Ospedaliera Pisana Università degli Studi di Pisa Pierluigi Paggiaro GINA International Executive Committee, Chairman GINA ITaly Cardio-Thoracic and Vascular Department,
More informationWEBINAR. Difficult-to-treat and severe asthma: changing the paradigm
WEBINAR Difficult-to-treat and severe asthma: changing the paradigm A multidisciplinary discussion on new therapies, and how to identify and manage difficult-to-treat and severe asthma DIFFICULT-TO-TREAT
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationTreating the right patient with the right
Asthma Getting it Right. Diagnosis, phenotypes, guidelines Treating the right patient with the right treatment Rama Vancheeswaran, FRCP, MSc Immunology, PhD Royal Free Hospital NHS Trust (Barnet site)
More informationASTHMA. Dr Liz Gamble BRI
ASTHMA Dr Liz Gamble BRI Diagnosis Clinical: wheeze, breathlessness, chest tightness, cough Variable airflow obstruction: peak flow chart, spirometry with reversibility to bronchodilators Airways hyper-responsiveness
More informationNational Asthma Educator Certification Board Detailed Content Outline
I. THE ASTHMA CONDITION 9 20 1 30 A. Pathophysiology 4 6 0 10 1. Teach an individual with asthma and their family using simple language by illustrating the following with appropriate educational aids a.
More informationSevere Asthma(s): Can THEY be prevented or reversed?
Severe Asthma(s): Can THEY be prevented or reversed? Sally Wenzel, MD Professor of Medicine UPMC Chair in Translational Airway Biology Disclosures Sally Wenzel, M.D. Grant/Research Support: Boehringer-Ingelheim,
More informationCynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters
Cynthia S. Kelly, M.D. Professor of Pediatrics Eastern Virginia Medical School Division Director Allergy Children s Hospital of The King s Daughters Disclosures Speakers bureau of Novartis and Genentech
More informationEvolution of asthma from childhood. Carlos Nunes Center of Allergy and Immunology of Algarve, PT
Evolution of asthma from childhood Carlos Nunes Center of Allergy and Immunology of Algarve, PT allergy@mail.telepac.pt Questionnaire data Symptoms occurring once or several times at follow-up (wheeze,
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationUsing Patient Characteristics to Individualize and Improve Asthma Care
Using Patient Characteristics to Individualize and Improve Asthma Care Leonard B. Bacharier, M.D. Associate Professor of Pediatrics Clinical Director, Division of Allergy, Immunology, & Pulmonary Medicine
More informationDiagnostics Assessment Programme. Measurement of exhaled nitric oxide concentration in asthma; NIOX MINO and NObreath. Final scope
Diagnostics Assessment Programme Measurement of exhaled nitric oxide concentration in asthma; NIOX MINO and NObreath Final scope February 2013 1. Introduction The Medical Technologies Advisory Committee
More informationPersonalized medicine in childhood asthma. Dr Mariëlle Pijnenburg, Erasmus MC Sophia, Rotterdam, NL
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationPredicting response to triamcinolone in severe asthma by machine learning: solving the Enigma
Page 1 of 5 Predicting response to triamcinolone in severe asthma by machine learning: solving the Enigma Kian Fan Chung National Heart & Lung Institute, Imperial College London & Royal Brompton and Harefield
More informationIs reslizumab effective in improving quality of life and asthma control in adolescent and adult patients with poorly controlled eosinophilic asthma?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2018 Is reslizumab effective in improving
More informationOutline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bronchial_thermoplasty 10/2010 3/2018 3/2019 3/2018 Description of Procedure or Service Bronchial thermoplasty
More informationRising Incidence of Asthma
Controlling Severe Asthma through Advanced Diagnosis and Treatment Strategies James F. Donohue, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine University of North Carolina at
More informationMeeting the Challenges of Asthma
Presenter Disclosure Information 11:05 11:45am Meeting the Challenge of Asthma SPEAKER Christopher Fanta, MD The following relationships exist related to this presentation: Christopher Fanta, MD: No financial
More informationEmerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationLocal Omalizumab Treatment Protocol (For children 6 to <12 years of age)
Local Omalizumab Treatment Protocol (For children 6 to
More informationOutcome, classification and management of wheezing in preschool children Paul L.P. Brand
Outcome, classification and management of wheezing in preschool children Paul L.P. Brand Princess Amalia Children s Clinic Isala klinieken, Zwolle the Netherlands p.l.p.brand@isala.nl Valle de la Luna,
More information10/24/2016. Precision Management of Severe Asthma How, When and Where. The Goals of Today s Presentation
1/24/216 Precision Management of Severe Asthma How, When and Where. Reynold A. Panettieri, Jr., MD Vice Chancellor for Clinical & Translational Science Director, Rutgers Institute for Translational and
More informationBiologicals in the management of bronchial asthma. Deepa Shrestha
Biologicals in the management of bronchial asthma Deepa Shrestha Overview of the seminar Burden of asthma and need of biologicals Immunology of asthma Possible targeted therapy Available biologicals used
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationDistinguishing Type-2 Asthma
UPDATE ON ASTHMA THERAPY: MATCHING PHENOTYPE TO TREATMENT Sally E. Wenzel, MD Professor of Medicine University of Pittsburgh Asthma Institute@UPMC Subsection Chief of Allergy 1234567 891234 567891 2345678
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: xolair_omalizumab 9/2003 11/2017 11/2018 11/2017 Description of Procedure or Service Asthma is a chronic
More informationNew TLD Indication: Asthma RELIEF-1 Study. Nick ten Hacken, MD Study Co-Principal Investigator
New TLD Indication: Asthma RELIEF-1 Study Nick ten Hacken, MD Study Co-Principal Investigator The Burden of Asthma WW Adult Asthma Prevalence 230.5 Million Mild/Intermittent 161.9 Million (70%) Moderate
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More information5/1/18. Emerging Challenges in Primary Care: The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes
Emerging Challenges in Primary Care: 2018 The Role of Type 2 Inflammation in Severe Asthma: Integrating Biologic Therapy to Optimize Outcomes 1 Faculty Diego J. Maselli, MD FCCP Assistant Professor of
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationNICE guideline Published: 29 November 2017 nice.org.uk/guidance/ng80
Asthma: diagnosis, monitoring and chronic asthma management NICE guideline Published: 29 November 2017 nice.org.uk/guidance/ng80 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationAntifungal treatment of severe asthma
Antifungal treatment of severe asthma David W. Denning University Hospital of South Manchester [Wythenshawe Hospital] The University of Manchester Severe asthma Bel EH, Severe asthma. Breath magazine Dec
More informationTreatment Options for Complicated/Severe Asthma. Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology
Treatment Options for Complicated/Severe Asthma Henry J. Kanarek, MD Kanarek Allergy Asthma Immunology www.kallergy.com 913-451-8555 Asthma Epidemiology World Health Organization, Asthma is one of the
More informationAsthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management
Asthma Phenotypes, Heterogeneity and Severity: The Basis of Asthma Management Eugene R. Bleecker, MD Professor and Director, Center for Genomics & Personalized Medicine Research Professor, Translational
More information